Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2020 / 06:45PM GMT
Release Date Price: $141.5 (+0.78%)
David Reed Risinger;Bruce C. Cozadd
Morgan Stanley, Research Division - MD in Equity Research and United States Pharmaceuticals Analyst;Jazz Pharmaceuticals plc - Co-Founder, Chairman &

Good afternoon, everyone. Thank you so much for joining us for the session with Jazz Pharmaceuticals. It's very much my pleasure to welcome Bruce Cozadd, who's Chairman and CEO. He cofounded Jazz in 2003 and has served as the Chairman and Chief Executive Officer since 2009 and also joining him is Rob Iannone, who is the Executive Vice President and Head of Research at Jazz, which has obviously become a much more important role given the company's pipeline progress. I do need to refer you to disclaimers at www.morganstanley.com/researchdisclosures. And if you're a member of the press, we ask you to disconnect and reach out to the Morgan Stanley Public Relations team.

And so with that, why don't I turn it over to you, Bruce, to provide some opening comments and then we'll take it from there?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot